Organizers:
Jon Sayers (University of Sheffield, UK)
Michael Dyson (The Wellcome Trust Sanger Institute, UK)
Alan Wallace (AstraZeneca, UK)
The Darwin Trust of Edinburgh
The genomics of restriction and modification
Rich Roberts (New England Biolabs, USA )
Combinatorial and evolutionary design of new proteins
Andreas Plückthun (University of Zürich, Switzerland)
Engineering antibodies for human therapy - Considerations
Dee Athwal (Celltech, UK)
15:10 - 15:40 Coffee/tea break
Supporting the discovery of potent and selective inhibitors of the novel target immunouppression, Monocarboxylate Transporter 1 (MCT1): the impact of molecular biology on drug discovery
Selected oral communication - Graham Belfield (AstraZeneca, UK)
Lead optimisation of antibody drugs by ribosome and phage display
Selected oral communication - Leeanne Cripps (Cambridge Antibody Technology, UK)
David Dryden (University of Edinburgh, UK)
AstraZeneca Award Lecture
The ¿impact (factor)¿ of phage lambda ¿ from restriction to recombineering?
Noreen Murray (University of Edinburgh, UK)
Poster session and drinks reception
Tn5 transposition: a molecular tool for studying protein structure/function
William Reznikoff (University of Wisconsin-Madison, USA)
Progress in artificial chromosome technology
Zoia Larin Monaco (University of Oxford, UK)
The development of signature-tagged mutagenesis (barcoding) and its use in studying Salmonella pathogenesis
David Holden (Imperial College London, UK)
11:00 - 11:30 Coffee/tea break
A network of orthogonal ribosome*mRNA pairs
Selected oral communication - Jason Chin (MRC-LMB, Cambridge, UK)
S-adenosylmethionine: jack of all trades and master of everything?
Selected oral communication - Wil Loenen (Leiden University, The Netherlands)
A recombinase mediated process for isothermal DNA amplification
Selected oral communication - Olaf Piepenburg (ASM Scientific Ltd, UK)
Mutant ES cell resource for the functional analysis of the mammalian genome
Bill Skarnes (The Wellcome Trust Sanger Institute, UK)
Creating an atlas of protein expression using recombinant antibodies in immunohistochemistry
John McCafferty (The Wellcome Trust Sanger Institute, UK)